This is just a quick announcement on the FDA’s new Clozapine Risk Evaluation and Management Strategy (REMS) program beginning soon. For the gunner docs in the country, here are the REMS Materials. For some reason there’s not an obvious link on the FDA page about it. The REMS materials, of course, “teach to the test” because we all want our patients with treatment-resistant schizophrenia (the main indication for clozapine) to have safe access to this medication.
One of the requirements for physicians will be familiarity with the guideline on clozapine and neutropenia for healthcare providers. It’s a 21 page pdf document. Then we have to pass a test, The Knowledge Assessment for Healthcare Providers and complete the prescriber enrollment form.